Inflammatory bowel disease and Clostridium difficile infection: contrasting views of international clinical professionals

Andreas Stallmach, Veli Jukka Anttila, Markus Hell, Simon Gwynn, Paloma Merino-Amador, Nicola Petrosillo, Zdenek Ráčil, Tim Warren, Christoph Wenisch, Mark Wilcox

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction In patients with inflammatory bowel disease (IBD), Clostridium difficile infection (CDI) is a risk factor for both morbidity and mortality. Currently, appropriate management is unclear. Guidance on best practice in the diagnosis and treatment of CDI in IBD patients is therefore needed. Methods A multidisciplinary group of clinicians involved in the treatment of patients with IBD and CDI developed 27 consensus statements. Respondents were asked to rate their agreement with each statement using a 4-point Likert scale. A modified Delphi methodology was used to review responses of 442 physicians from different specialties (including infectious disease specialists [n = 104], microbiologists [n = 95], and gastroenterologists [n = 73]). A threshold of 75 % agreement was predefined as consensus. Results Consensus was achieved for 17 of the 27 statements. Unprompted recognition of risk factors for CDI was low. Intensification of immunosuppressive therapy in the absence of clinical improvement was controversial. Clear definitions of treatment failure of antibiotic therapy in CDI and recurrence of CDI in IBD are needed. Respondents require further clarity regarding the place of fecal microbiota transplantation in CDI patients with IBD. Differences were observed between the perceptions of microbiologists and gastroenterologists, as well as between countries. Conclusions Different perceptions both between specialties and geographical locations complicate the development of an internationally accepted algorithm for the diagnosis and treatment of CDI in patients with IBD. This study highlights the need for future studies in this area.

Original languageEnglish
JournalZeitschrift fur Gastroenterologie
DOIs
Publication statusE-pub ahead of print - Feb 9 2018

Fingerprint

Clostridium Infections
Clostridium difficile
Inflammatory Bowel Diseases
Infectious Disease Medicine
Therapeutics
Immunosuppressive Agents
Treatment Failure
Practice Guidelines
Anti-Bacterial Agents
Morbidity
Physicians
Recurrence
Mortality

Keywords

  • Chronisch-entzündliche Darmerkrankung
  • Clostridium difficile Infektionen
  • Konsensbericht

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Inflammatory bowel disease and Clostridium difficile infection: contrasting views of international clinical professionals. / Stallmach, Andreas; Anttila, Veli Jukka; Hell, Markus; Gwynn, Simon; Merino-Amador, Paloma; Petrosillo, Nicola; Ráčil, Zdenek; Warren, Tim; Wenisch, Christoph; Wilcox, Mark.

In: Zeitschrift fur Gastroenterologie, 09.02.2018.

Research output: Contribution to journalArticle

Stallmach, Andreas ; Anttila, Veli Jukka ; Hell, Markus ; Gwynn, Simon ; Merino-Amador, Paloma ; Petrosillo, Nicola ; Ráčil, Zdenek ; Warren, Tim ; Wenisch, Christoph ; Wilcox, Mark. / Inflammatory bowel disease and Clostridium difficile infection: contrasting views of international clinical professionals. In: Zeitschrift fur Gastroenterologie. 2018.
@article{00528a5da2634712825f1bf12d831cd9,
title = "Inflammatory bowel disease and Clostridium difficile infection:: contrasting views of international clinical professionals",
abstract = "Introduction In patients with inflammatory bowel disease (IBD), Clostridium difficile infection (CDI) is a risk factor for both morbidity and mortality. Currently, appropriate management is unclear. Guidance on best practice in the diagnosis and treatment of CDI in IBD patients is therefore needed. Methods A multidisciplinary group of clinicians involved in the treatment of patients with IBD and CDI developed 27 consensus statements. Respondents were asked to rate their agreement with each statement using a 4-point Likert scale. A modified Delphi methodology was used to review responses of 442 physicians from different specialties (including infectious disease specialists [n = 104], microbiologists [n = 95], and gastroenterologists [n = 73]). A threshold of 75 {\%} agreement was predefined as consensus. Results Consensus was achieved for 17 of the 27 statements. Unprompted recognition of risk factors for CDI was low. Intensification of immunosuppressive therapy in the absence of clinical improvement was controversial. Clear definitions of treatment failure of antibiotic therapy in CDI and recurrence of CDI in IBD are needed. Respondents require further clarity regarding the place of fecal microbiota transplantation in CDI patients with IBD. Differences were observed between the perceptions of microbiologists and gastroenterologists, as well as between countries. Conclusions Different perceptions both between specialties and geographical locations complicate the development of an internationally accepted algorithm for the diagnosis and treatment of CDI in patients with IBD. This study highlights the need for future studies in this area.",
keywords = "Chronisch-entz{\"u}ndliche Darmerkrankung, Clostridium difficile Infektionen, Konsensbericht",
author = "Andreas Stallmach and Anttila, {Veli Jukka} and Markus Hell and Simon Gwynn and Paloma Merino-Amador and Nicola Petrosillo and Zdenek R{\'a}čil and Tim Warren and Christoph Wenisch and Mark Wilcox",
year = "2018",
month = "2",
day = "9",
doi = "10.1055/s-0044-100045",
language = "English",
journal = "Zeitschrift fur Gastroenterologie",
issn = "0044-2771",
publisher = "Karl Demeter Verlag GmbH",

}

TY - JOUR

T1 - Inflammatory bowel disease and Clostridium difficile infection:

T2 - contrasting views of international clinical professionals

AU - Stallmach, Andreas

AU - Anttila, Veli Jukka

AU - Hell, Markus

AU - Gwynn, Simon

AU - Merino-Amador, Paloma

AU - Petrosillo, Nicola

AU - Ráčil, Zdenek

AU - Warren, Tim

AU - Wenisch, Christoph

AU - Wilcox, Mark

PY - 2018/2/9

Y1 - 2018/2/9

N2 - Introduction In patients with inflammatory bowel disease (IBD), Clostridium difficile infection (CDI) is a risk factor for both morbidity and mortality. Currently, appropriate management is unclear. Guidance on best practice in the diagnosis and treatment of CDI in IBD patients is therefore needed. Methods A multidisciplinary group of clinicians involved in the treatment of patients with IBD and CDI developed 27 consensus statements. Respondents were asked to rate their agreement with each statement using a 4-point Likert scale. A modified Delphi methodology was used to review responses of 442 physicians from different specialties (including infectious disease specialists [n = 104], microbiologists [n = 95], and gastroenterologists [n = 73]). A threshold of 75 % agreement was predefined as consensus. Results Consensus was achieved for 17 of the 27 statements. Unprompted recognition of risk factors for CDI was low. Intensification of immunosuppressive therapy in the absence of clinical improvement was controversial. Clear definitions of treatment failure of antibiotic therapy in CDI and recurrence of CDI in IBD are needed. Respondents require further clarity regarding the place of fecal microbiota transplantation in CDI patients with IBD. Differences were observed between the perceptions of microbiologists and gastroenterologists, as well as between countries. Conclusions Different perceptions both between specialties and geographical locations complicate the development of an internationally accepted algorithm for the diagnosis and treatment of CDI in patients with IBD. This study highlights the need for future studies in this area.

AB - Introduction In patients with inflammatory bowel disease (IBD), Clostridium difficile infection (CDI) is a risk factor for both morbidity and mortality. Currently, appropriate management is unclear. Guidance on best practice in the diagnosis and treatment of CDI in IBD patients is therefore needed. Methods A multidisciplinary group of clinicians involved in the treatment of patients with IBD and CDI developed 27 consensus statements. Respondents were asked to rate their agreement with each statement using a 4-point Likert scale. A modified Delphi methodology was used to review responses of 442 physicians from different specialties (including infectious disease specialists [n = 104], microbiologists [n = 95], and gastroenterologists [n = 73]). A threshold of 75 % agreement was predefined as consensus. Results Consensus was achieved for 17 of the 27 statements. Unprompted recognition of risk factors for CDI was low. Intensification of immunosuppressive therapy in the absence of clinical improvement was controversial. Clear definitions of treatment failure of antibiotic therapy in CDI and recurrence of CDI in IBD are needed. Respondents require further clarity regarding the place of fecal microbiota transplantation in CDI patients with IBD. Differences were observed between the perceptions of microbiologists and gastroenterologists, as well as between countries. Conclusions Different perceptions both between specialties and geographical locations complicate the development of an internationally accepted algorithm for the diagnosis and treatment of CDI in patients with IBD. This study highlights the need for future studies in this area.

KW - Chronisch-entzündliche Darmerkrankung

KW - Clostridium difficile Infektionen

KW - Konsensbericht

UR - http://www.scopus.com/inward/record.url?scp=85042185611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042185611&partnerID=8YFLogxK

U2 - 10.1055/s-0044-100045

DO - 10.1055/s-0044-100045

M3 - Article

AN - SCOPUS:85042185611

JO - Zeitschrift fur Gastroenterologie

JF - Zeitschrift fur Gastroenterologie

SN - 0044-2771

ER -